Efficacy of Polyethylene Glycol Loxenatide combined with Exercise for sarcopenia in Type 2 Diabetes Patients:A randomized controlled trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300071939

Enrollment

Unknown

Registered

2023-05-30

Start date

2023-05-30

Completion date

Unknown

Last updated

2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sen-Mei China Diabetes Research Fund

Interventions

Glycol Loxenatide combined with Exercise study group:Glycol Loxenatide combined with Exercise

Exercise control group:Exercise

Eligibility

Sex/Gender

All

Age

60 Years to 75 Years

Inclusion criteria

Inclusion criteria: ? Type 2 diabetes patients; ? Age: 60-75 years old; Both male and female; ? Using DXA to measure skeletal muscle mass, ASMI=limb skeletal muscle mass (kg)/height 2 (m2), diagnostic criteria for muscle mass reduction: ASMI<7.0kg/m2 for males and<5.4kg/m2 for females; ? HbA1c:7.0-10.0%; ? Using oral antidiabetic drugs alone or in combination, the scheme has remained stable for nearly 3 months; ? The subjects voluntarily participate and sign an informed consent form, and are able to comply with the requirements of the research protocol.

Exclusion criteria

Exclusion criteria: ? Has a history of allergies to polyethylene glycol losenside or drugs with similar chemical structures; ? Type 1 or secondary diabetes patients; ? The oral hypoglycemic drug regimen includes DPP-4 enzyme inhibitors, ? The hypoglycemic treatment plan includes GLP-1RA and/or insulin, ? Serious heart, liver and kidney function damage, serious nervous system disease, vascular disease or bone and joint disease; ? Long term bed rest, infectious diseases or tumors; ? Suffering from autoimmune diseases; ? Acute disease (such as acute pancreatitis, diabetes ketoacidosis, acute myocardial infarction, cerebral hemorrhage and cerebral infarction) 6 months before the test; ? Having cognitive impairment; ? Have a history of application of thyroid hormone, growth hormone, glucocorticoid or sex hormone; ? Individuals who have participated in clinical research on other drugs within 3 months prior to the trial.

Design outcomes

Primary

Measure	Time frame
muscel mass;	—

Secondary

Measure	Time frame
VFA;A/G;VAT /SAT;FPG;HbA1c;	—

Countries

China

Contacts

Public ContactLiu-Zhelong

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

liuzhelong@163.com+86 139 8623 5028

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026